Safety and Efficacy of Kelulut Honey Eyedrops in Dry Eye Disease

NCT ID: NCT07279324

Last Updated: 2025-12-12

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-04-01
• Study Completion Date: 2026-10-30

Brief Summary

The goal of this clinical trial is to learn whether Kelulut honey eyedrops are safe and helpful in treating dry eye disease in adults. It will also learn about any side effects that may occur with the use of Kelulut honey eyedrops.

This Kelulut honey eyedrops are sterile ophthalmic solutions formulated with honey derived from stingless bees (Trigona spp.) at concentrations of 12.5% 25% and 50%. The eyedrop formulations are prepared according to a standardized laboratory protocol to ensure sterility, stability, and suitability for ocular use. Full formulation details are proprietary but can be provided to the ethics committee or regulatory authorities upon request.

The main questions this clinical trial aims to answer are:

1. Does Kelulut honey improve tear film stability and dry eye symptoms?

2. Are Kelulut honey eyedrops safe and well tolerated on the ocular surface?

Researchers will compare different concentrations of Kelulut honey eyedrops to determine which concentration provides the best balance of safety and clinical benefit.

Participants will:

1. Use Kelulut honey eyedrops (12.5%, 25%, or 50%) three times daily for 1 month, in addition to continuing their usual dry eye treatments.

2. Attend scheduled follow-up visits (on week 2 and week 4) for eye examinations and dry eye assessments (e.g., TBUT, ocular surface staining, Schirmer test, and OSDI).

3. Report any changes in symptoms or any discomfort, including stinging, redness, irritation, or other adverse effects experienced during the study.

Conditions

Dry Eye Disease (DED); Dry Eye Syndrome (DES); Dry Eye Symptoms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

KHED 12.5%

Participants in this arm will use Kelulut honey eyedrops formulated with Kelulut honey derived from stingless bees (Trigona spp.) at a concentration of 12.5%. The eyedrops will be administered three times daily for 1 month, in addition to the participant's usual dry eye treatments. Safety, tolerability, and changes in tear film parameters will be assessed.

Group Type: EXPERIMENTAL

Kelulut Honey Eyedrop 12.5%

Intervention Type: DRUG

KHED 12.5% is sterile ophthalmic solution containing Kelulut honey derived from stingless bees (Trigona spp.) at a concentration of 12.5%. Participants will instill one drop in each eye three times daily for 30 days, in addition to their usual dry eye treatments.

KHED 25%

Participants in this arm will use Kelulut honey eyedrops formulated with Kelulut honey derived from stingless bees (Trigona spp.) at a concentration of 25%. The eyedrops will be administered three times daily for 1 month, in addition to the participant's usual dry eye treatments. Safety, tolerability, and changes in tear film parameters will be assessed.

Group Type: EXPERIMENTAL

Kelulut Honey Eyedrop 25%

Intervention Type: DRUG

KHED 25% is sterile ophthalmic solution containing Kelulut honey derived from stingless bees (Trigona spp.) at a concentration of 25%. Participants will instill one drop in each affected eye three times daily for 30 days, in addition to their usual dry eye treatments.

KHED 50%

Participants in this arm will use Kelulut honey eyedrops formulated with Kelulut honey derived from stingless bees (Trigona spp.) at a concentration of 50%. The eyedrops will be administered three times daily for 1 month, in addition to the participant's usual dry eye treatments. Safety, tolerability, and changes in tear film parameters will be assessed.

Group Type: EXPERIMENTAL

Kelulut Honey Eyedrop 50%

Intervention Type: DRUG

KHED 50% is sterile ophthalmic solution containing Kelulut honey derived from stingless bees (Trigona spp.) at a concentration of 25%. Participants will instill one drop in each affected eye three times daily for 30 days, in addition to their usual dry eye treatments

Interventions

Kelulut Honey Eyedrop 12.5%

KHED 12.5% is sterile ophthalmic solution containing Kelulut honey derived from stingless bees (Trigona spp.) at a concentration of 12.5%. Participants will instill one drop in each eye three times daily for 30 days, in addition to their usual dry eye treatments.

Intervention Type: DRUG

Kelulut Honey Eyedrop 25%

KHED 25% is sterile ophthalmic solution containing Kelulut honey derived from stingless bees (Trigona spp.) at a concentration of 25%. Participants will instill one drop in each affected eye three times daily for 30 days, in addition to their usual dry eye treatments.

Intervention Type: DRUG

Kelulut Honey Eyedrop 50%

KHED 50% is sterile ophthalmic solution containing Kelulut honey derived from stingless bees (Trigona spp.) at a concentration of 25%. Participants will instill one drop in each affected eye three times daily for 30 days, in addition to their usual dry eye treatments

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age 18-50 years at the time of consent.

2. Clinical diagnosis of dry eye disease in at least one eye, based on symptoms and clinical signs (Symptomatic dry eye, defined as an OSDI score ≥ 13; objective evidence of tear film instability, such as TBUT < 10 seconds in at least one eye)

3. Participants may be Treatment-naïve, OR on stable dry eye treatment for at least 2 weeks before enrollment.

4. Willing to use Kelulut honey eyedrops three times daily for 1 month as instructed.

5. Able and willing to attend all study visits (Baseline, Week 2, Week 4).

Exclusion Criteria

1. Known allergy or hypersensitivity to honey, bee products, or any component of the study formulations.

2. Active ocular infection or inflammation (e.g., infectious conjunctivitis, keratitis, uveitis).

3. Severe allergic conjunctivitis or other ocular surface diseases

4. Significant meibomian gland dysfunction or blepharitis

5. Ocular surgery or laser procedures within the past 6 months.

6. Use of topical ocular medications other than lubricants within the past 30 days

7. Contact lens wear within 1 week prior to baseline or expected during the study.

8. Punctal plugs or other lacrimal procedures within the last 3 months.

9. Systemic diseases that significantly affect the ocular surface and are unstable or uncontrolled (e.g., uncontrolled Sjögren's, uncontrolled rheumatoid arthritis, uncontrolled diabetes).

10. Participation in another clinical trial or receipt of an investigational product within the past 30 days.

11. Pregnant or breastfeeding women, or those planning pregnancy during the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Universiti Sains Malaysia

OTHER

Sponsor Role: lead

Responsible Party

Shahidatul Adha Mohamad

Dr.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Hospital Pakar Universiti Sains Malaysia

Kota Bharu, Kelantan, Malaysia

Countries

Malaysia

Central Contacts

Shahidatul Adha Mohamad Dr, MD, MMed

Role: CONTACT

shieda@usm.my

+609-767 6362

Other Identifiers

USM-KHED-2025-01

Identifier Type: -

Identifier Source: org_study_id